| Assessment Status | Rapid Review Complete |
| HTA ID | 26018 |
| Drug | Durvalumab |
| Brand | Imfinzi® |
| Indication | Durvalumab (Imfinzi®) in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient. |
| Assessment Process | |
| Rapid review commissioned | 10/04/2026 |
| Rapid review completed | 15/05/2026 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that durvalumab not be considered for reimbursement at the submitted price*. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here